• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Wave Life Sciences (WVE) Is Down 5.2% After Wider Q2 Losses And RNA Editing Updates - What's Changed

    Simply Wall St·08/02/2026 22:19:34
    Listen to the news
    • In late July 2026, Wave Life Sciences reported Q2 2026 results showing sales of US$2.27 million versus US$8.70 million a year earlier, with net loss widening to US$69.36 million and basic loss per share from continuing operations at US$0.34.
    • Despite weaker quarterly revenue, the company highlighted progress in its RNAi and RNA editing programs, including positive data for obesity candidate WVE-007 and preparations for an FDA meeting on a potential accelerated approval pathway for AATD therapy WVE-006.
    • We’ll now explore how this combination of deeper quarterly losses and encouraging RNA editing progress, especially around WVE-006, reshapes Wave’s investment narrative.

    The latest GPUs need a type of rare earth metal called Neodymium and there are only 29 companies in the world exploring or producing it. Find the list for free.

    Wave Life Sciences Investment Narrative Recap

    To own Wave Life Sciences today, you need to believe that its RNA editing and RNAi platforms, led by AATD candidate WVE-006 and obesity program WVE-007, can eventually justify ongoing heavy losses. The latest quarter showed a deeper net loss of US$69.36 million and sharply lower Q2 sales of US$2.27 million, which keeps liquidity and future dilution as the key near term risk. The most important near term catalyst remains upcoming FDA feedback on a potential accelerated approval path for WVE-006, and this update was not meaningfully changed by the Q2 figures.

    Among recent announcements, the May 2026 RestorAATion-2 data for WVE-006 stands out as most relevant here, because it underpins that FDA meeting. Dose dependent Z AAT reductions of up to 70.5% and restoration of functional M AAT to therapeutically relevant levels, together with a clean safety profile, are central to any accelerated approval argument. Against Q2’s wider losses, this dataset is what continues to support the case that WVE-006 could be a value defining program if it progresses as planned.

    Yet beneath the encouraging WVE-006 data, the combination of widening losses and reliance on non recurring revenue is something investors should be very aware of...

    Read the full narrative on Wave Life Sciences (it's free!)

    Wave Life Sciences’ narrative projects $177.3 million revenue and $38.9 million earnings by 2029.

    Uncover how Wave Life Sciences' forecasts yield a $19.62 fair value, a 256% upside to its current price.

    Exploring Other Perspectives

    WVE 1-Year Stock Price Chart
    WVE 1-Year Stock Price Chart

    Some of the lowest ranked analysts go much further on the downside, previously modeling revenue shrinking about 25% a year and still not seeing profitability within three years. When you compare that with the recent drop in Q2 sales to US$2.27 million and the deepening losses, it shows how widely views can differ and why it is worth looking at several possible paths, not just the consensus one.

    Explore 3 other fair value estimates on Wave Life Sciences - why the stock might be worth over 7x more than the current price!

    Decide For Yourself

    Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

    Interested In Other Possibilities?

    Our daily scans reveal stocks with breakout potential. Don't miss this chance:

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.